JP2014508780A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014508780A5 JP2014508780A5 JP2013557916A JP2013557916A JP2014508780A5 JP 2014508780 A5 JP2014508780 A5 JP 2014508780A5 JP 2013557916 A JP2013557916 A JP 2013557916A JP 2013557916 A JP2013557916 A JP 2013557916A JP 2014508780 A5 JP2014508780 A5 JP 2014508780A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- skin
- improve
- scleroderma
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161451995P | 2011-03-11 | 2011-03-11 | |
| US61/451,995 | 2011-03-11 | ||
| US201161480272P | 2011-04-28 | 2011-04-28 | |
| US61/480,272 | 2011-04-28 | ||
| PCT/US2012/028538 WO2012125475A1 (en) | 2011-03-11 | 2012-03-09 | Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2-6-dione in treatment of immune-related and inflammatory diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016248598A Division JP2017081959A (ja) | 2011-03-11 | 2016-12-22 | 免疫関連疾患及び炎症性疾患の治療における３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014508780A JP2014508780A (ja) | 2014-04-10 |
| JP2014508780A5 true JP2014508780A5 (enExample) | 2015-04-23 |
| JP6118273B2 JP6118273B2 (ja) | 2017-04-19 |
Family
ID=45876915
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013557916A Expired - Fee Related JP6118273B2 (ja) | 2011-03-11 | 2012-03-09 | 免疫関連疾患及び炎症性疾患の治療における３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンの使用 |
| JP2013557904A Withdrawn JP2014510078A (ja) | 2011-03-11 | 2012-03-09 | ３−（５−アミノ−２−メチル−４−オキソ−４ｈ−キナゾリン−３−イル）−ピペリジン−２，６−ジオンを用いる癌の治療方法 |
| JP2016248598A Pending JP2017081959A (ja) | 2011-03-11 | 2016-12-22 | 免疫関連疾患及び炎症性疾患の治療における３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンの使用 |
| JP2017009923A Expired - Fee Related JP6348192B2 (ja) | 2011-03-11 | 2017-01-24 | ３−（５−アミノ−２−メチル−４−オキソ−４ｈ−キナゾリン−３−イル）−ピペリジン−２，６−ジオンを用いる癌の治療方法 |
| JP2018103019A Withdrawn JP2018168159A (ja) | 2011-03-11 | 2018-05-30 | ３−（５−アミノ−２−メチル−４−オキソ−４ｈ−キナゾリン−３−イル）−ピペリジン−２，６−ジオンを用いる癌の治療方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013557904A Withdrawn JP2014510078A (ja) | 2011-03-11 | 2012-03-09 | ３−（５−アミノ−２−メチル−４−オキソ−４ｈ−キナゾリン−３−イル）−ピペリジン−２，６−ジオンを用いる癌の治療方法 |
| JP2016248598A Pending JP2017081959A (ja) | 2011-03-11 | 2016-12-22 | 免疫関連疾患及び炎症性疾患の治療における３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンの使用 |
| JP2017009923A Expired - Fee Related JP6348192B2 (ja) | 2011-03-11 | 2017-01-24 | ３−（５−アミノ−２−メチル−４−オキソ−４ｈ−キナゾリン−３−イル）−ピペリジン−２，６−ジオンを用いる癌の治療方法 |
| JP2018103019A Withdrawn JP2018168159A (ja) | 2011-03-11 | 2018-05-30 | ３−（５−アミノ−２−メチル−４−オキソ−４ｈ−キナゾリン−３−イル）−ピペリジン−２，６−ジオンを用いる癌の治療方法 |
Country Status (29)
| Country | Link |
|---|---|
| US (6) | US8906932B2 (enExample) |
| EP (3) | EP2683384B1 (enExample) |
| JP (5) | JP6118273B2 (enExample) |
| KR (2) | KR20140025374A (enExample) |
| CN (3) | CN107375293A (enExample) |
| AR (1) | AR085651A1 (enExample) |
| AU (4) | AU2012229316B2 (enExample) |
| BR (2) | BR112013023280A2 (enExample) |
| CA (2) | CA2829593A1 (enExample) |
| CY (1) | CY1117430T1 (enExample) |
| DK (1) | DK2683384T3 (enExample) |
| EA (2) | EA201691939A1 (enExample) |
| ES (2) | ES2659205T3 (enExample) |
| HR (1) | HRP20160056T1 (enExample) |
| HU (1) | HUE027481T2 (enExample) |
| IL (2) | IL227990B (enExample) |
| MX (2) | MX2013010217A (enExample) |
| NI (2) | NI201300082A (enExample) |
| PH (2) | PH12013501820A1 (enExample) |
| PL (1) | PL2683384T3 (enExample) |
| PT (1) | PT2683384E (enExample) |
| RS (1) | RS54553B1 (enExample) |
| RU (3) | RU2017120977A (enExample) |
| SG (2) | SG192947A1 (enExample) |
| SI (1) | SI2683384T1 (enExample) |
| SM (1) | SMT201600034B (enExample) |
| TW (2) | TW201700100A (enExample) |
| WO (2) | WO2012125459A1 (enExample) |
| ZA (2) | ZA201306148B (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102898416A (zh) | 2006-09-26 | 2013-01-30 | 细胞基因公司 | 作为抗肿瘤剂的5-取代的喹唑酮衍生物 |
| US20120134969A1 (en) | 2009-05-25 | 2012-05-31 | Hiroshi Handa | Pharmaceutical composition containing nuclear factor involved in proliferation and differentiation of central neuronal cells |
| EA026100B1 (ru) | 2011-03-11 | 2017-03-31 | Селджин Корпорейшн | Твердые формы 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2,6-диона и их фармацевтические композиции и применение |
| AU2012236655B2 (en) | 2011-03-28 | 2016-09-22 | Deuterx, Llc, | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
| CN103688176A (zh) * | 2011-04-29 | 2014-03-26 | 细胞基因公司 | 利用cereblon作为预报因子治疗癌和炎性疾病的方法 |
| ES2872967T3 (es) | 2012-06-29 | 2021-11-03 | Celgene Corp | Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS) |
| EP2882442B1 (en) * | 2012-08-09 | 2021-06-09 | Celgene Corporation | Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
| US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
| US9682952B2 (en) | 2012-09-04 | 2017-06-20 | Celgene Corporation | Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl) piperidine-2-6-dione and methods of preparation thereof |
| CN104797256A (zh) * | 2012-09-10 | 2015-07-22 | 细胞基因公司 | 用于治疗局部晚期乳腺癌的方法 |
| CA2935495C (en) | 2013-01-14 | 2021-04-20 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
| EP2968334A4 (en) | 2013-03-14 | 2016-08-03 | Deuterx Llc | 3- (SUBSTITIERTES-4-OXO-quinazolin-3 (4H) -yl) -3-deutero-PIPERIDINE-2,6-DIONE DERIVATIVES |
| MX368286B (es) * | 2013-04-17 | 2019-09-27 | Signal Pharm Llc | Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer. |
| KR102242505B1 (ko) * | 2013-04-17 | 2021-04-20 | 시그날 파마소티칼 엘엘씨 | 암 치료용 tor 키나제 억제제 및 시티딘 유사체를 포함하는 병용 요법 |
| WO2014179416A1 (en) * | 2013-05-01 | 2014-11-06 | Celgene Corporation | Synthesis of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2,6-dione |
| JP2016521280A (ja) * | 2013-05-03 | 2016-07-21 | セルジーン コーポレイション | 併用療法を用いて癌を治療する方法 |
| US20160282354A1 (en) | 2013-11-08 | 2016-09-29 | The Broad Institute, Inc. | Compositions and methods for selecting a treatment for b-cell neoplasias |
| EA201691144A1 (ru) * | 2013-12-06 | 2016-11-30 | Селджин Корпорейшн | Способы определения эффективности лекарственного средства для лечения диффузной крупноклеточной b-клеточной лимфомы, множественной миеломы и злокачественных новообразований миелоидного ростка |
| TW201540323A (zh) * | 2014-01-15 | 2015-11-01 | Celgene Corp | ３－（５－胺基－２－甲基－４－側氧基－４ｈ－喹唑啉－３－基）－哌啶－２，６－二酮之調配物 |
| JP6640126B2 (ja) | 2014-06-27 | 2020-02-05 | セルジーン コーポレイション | セレブロン及び他のｅ３ユビキチンリガーゼの立体構造の変化を誘導するための組成物及び方法 |
| CA2954652A1 (en) * | 2014-07-11 | 2016-01-14 | Celgene Corporation | Combination therapy for cancer |
| LT3182996T (lt) | 2014-08-22 | 2023-03-10 | Celgene Corporation | Daugybinės mielomos gydymo būdai imunomoduliuojančiais junginiais derinyje su antikūnais |
| CA2966753A1 (en) * | 2014-11-17 | 2016-05-26 | Arno Therapeutics, Inc. | Onapristone extended-release compositions and methods |
| TW201642857A (zh) * | 2015-04-06 | 2016-12-16 | 西建公司 | 以組合療法治療肝細胞癌 |
| BR112017028530A2 (pt) * | 2015-07-02 | 2018-08-28 | Celgene Corp | terapia combinada para tratamento de cânceres hematológicos e tumores sólidos |
| US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
| KR20180039084A (ko) | 2015-08-27 | 2018-04-17 | 셀진 코포레이션 | 3-(5-아미노-2-메틸-4-옥소-4h-퀴나졸린-3-일)-피페리딘-2,6-다이온을 포함하는 약제학적 조성물 |
| US11459613B2 (en) | 2015-09-11 | 2022-10-04 | The Brigham And Women's Hospital, Inc. | Methods of characterizing resistance to modulators of Cereblon |
| AU2016326657B2 (en) | 2015-09-25 | 2019-10-24 | Context Biopharma, Inc. | Methods of making onapristone intermediates |
| MX2018006779A (es) * | 2015-12-02 | 2018-08-01 | Celgene Corp | Terapia ciclica con 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-p iperidin-2,6-diona. |
| CA3008422A1 (en) | 2015-12-15 | 2017-06-22 | Context Biopharma Inc. | Amorphous onapristone compositions and methods of making the same |
| US10830762B2 (en) | 2015-12-28 | 2020-11-10 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases |
| RU2730500C2 (ru) | 2016-01-14 | 2020-08-24 | Канпу Биофармасьютикалз, Лтд | Производное хиназолинона, способ его получения, фармацевтическая композиция и применения |
| CA3017740A1 (en) * | 2016-03-16 | 2017-09-21 | Pearlie BURNETTE | Small molecules against cereblon to enhance effector t cell function |
| US20180148471A1 (en) | 2016-11-30 | 2018-05-31 | Arno Therapeutics, Inc. | Methods for onapristone synthesis dehydration and deprotection |
| WO2018165142A1 (en) * | 2017-03-07 | 2018-09-13 | Celgene Corporation | Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses |
| EP3641772B1 (en) | 2017-06-22 | 2023-08-02 | Celgene Corporation | Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection |
| WO2019077968A1 (en) | 2017-10-18 | 2019-04-25 | Canon Kabushiki Kaisha | PACKAGING CONTAINER AND PACKAGE |
| WO2019191451A1 (en) * | 2018-03-30 | 2019-10-03 | Biotheryx, Inc. | Thienopyrimidinone compounds |
| US11730726B2 (en) | 2018-07-11 | 2023-08-22 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Dimeric immuno-modulatory compounds against cereblon-based mechanisms |
| EP3848371A4 (en) * | 2018-09-07 | 2022-06-08 | Medshine Discovery Inc. | TRICYCLIC FURAN-SUBSTITUTED PIPERIDONEE COMPOUND |
| AU2019351811B2 (en) | 2018-10-01 | 2025-01-02 | Celgene Corporation | Combination therapy for the treatment of cancer |
| JP7300687B2 (ja) * | 2019-03-22 | 2023-06-30 | ユニヴァーシティー オブ ウルサン ファウンデイション フォー インダストリー コーオペレイション | 肝細胞癌診断用バイオマーカーセレブロンと、これに特異的な新規なモノクローナル抗体 |
| US20230150978A1 (en) * | 2020-03-30 | 2023-05-18 | Enyo Pharma | Quinazolinone derivatives and uses thereof for treating a cancer |
| TW202416995A (zh) * | 2022-08-16 | 2024-05-01 | 比利時商艾托斯比利時公司 | 用於治療與至少一種抗體分泌細胞標記物之表現相關的疾病的腺苷受體拮抗劑及其組合物 |
| CN118844365A (zh) * | 2024-06-26 | 2024-10-29 | 华南理工大学 | 一种化疗诱发的血液毒性斑马鱼模型及其应用 |
| CN119161336B (zh) * | 2024-07-24 | 2025-09-05 | 四川大学 | 一种作为Blimp1抑制剂的小分子化合物及其用途 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| KR890002631B1 (ko) | 1984-10-04 | 1989-07-21 | 몬산토 캄파니 | 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물 |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
| JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| US5360352A (en) | 1992-12-24 | 1994-11-01 | The Whitaker Corporation | Wire retainer for current mode coupler |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| DE69632684T2 (de) | 1995-06-27 | 2005-06-09 | Takeda Pharmaceutical Co. Ltd. | Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung |
| TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
| JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| EP0839525B1 (en) | 1996-10-31 | 2004-08-04 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| DK0946169T3 (da) | 1996-12-20 | 2003-04-22 | Takeda Chemical Industries Ltd | Fremgangsmåde til fremstilling af et præparat med vedvarende frigivelse |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| AU1325102A (en) | 2000-10-16 | 2002-04-29 | Phylos Inc | Protein scaffolds for antibody mimics and other binding proteins |
| AU2002226366B2 (en) * | 2000-12-06 | 2007-03-22 | Laboratoires Serono Sa | Use of SARP-1 for the treatment and/or prevention of scleroderma |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| PT1390535E (pt) | 2001-04-26 | 2010-10-04 | Amgen Mountain View Inc | Bibliotecas combinatórias de domínios monoméricos |
| US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| WO2006055689A2 (en) | 2004-11-16 | 2006-05-26 | Avidia Research Institute | Protein scaffolds and uses thereof |
| US20080051379A1 (en) | 2004-12-01 | 2008-02-28 | Trustees Of Boston University | Compositions and Methods for the Treatment of Peripheral B-Cell Neoplasms |
| CN102898416A (zh) * | 2006-09-26 | 2013-01-30 | 细胞基因公司 | 作为抗肿瘤剂的5-取代的喹唑酮衍生物 |
| GB0709092D0 (en) * | 2007-05-11 | 2007-06-20 | Borrebaeck Carl | Diagnosis and method of disease |
| KR101593242B1 (ko) * | 2007-09-26 | 2016-02-11 | 셀진 코포레이션 | ６-, ７- 또는 ８-치환된 퀴나졸리논 유도체, 및 그를 포함하는 조성물 및 그의 사용 방법 |
| WO2009075795A1 (en) * | 2007-12-07 | 2009-06-18 | Celgene Corporation | Biomarkers for monitoring the treatment by quinazolinone compounds |
| US20120134969A1 (en) | 2009-05-25 | 2012-05-31 | Hiroshi Handa | Pharmaceutical composition containing nuclear factor involved in proliferation and differentiation of central neuronal cells |
| CN103688176A (zh) * | 2011-04-29 | 2014-03-26 | 细胞基因公司 | 利用cereblon作为预报因子治疗癌和炎性疾病的方法 |
-
2012
- 2012-03-09 CA CA 2829593 patent/CA2829593A1/en not_active Abandoned
- 2012-03-09 RU RU2017120977A patent/RU2017120977A/ru not_active Application Discontinuation
- 2012-03-09 ES ES12710411.5T patent/ES2659205T3/es active Active
- 2012-03-09 US US13/417,088 patent/US8906932B2/en not_active Expired - Fee Related
- 2012-03-09 SG SG2013064373A patent/SG192947A1/en unknown
- 2012-03-09 CN CN201710232755.8A patent/CN107375293A/zh active Pending
- 2012-03-09 PH PH1/2013/501820A patent/PH12013501820A1/en unknown
- 2012-03-09 PL PL12710836T patent/PL2683384T3/pl unknown
- 2012-03-09 TW TW105111258A patent/TW201700100A/zh unknown
- 2012-03-09 KR KR20137026403A patent/KR20140025374A/ko not_active Ceased
- 2012-03-09 US US13/984,833 patent/US20140148473A1/en not_active Abandoned
- 2012-03-09 BR BR112013023280A patent/BR112013023280A2/pt not_active IP Right Cessation
- 2012-03-09 BR BR112013023277A patent/BR112013023277A2/pt not_active IP Right Cessation
- 2012-03-09 JP JP2013557916A patent/JP6118273B2/ja not_active Expired - Fee Related
- 2012-03-09 EP EP12710836.3A patent/EP2683384B1/en active Active
- 2012-03-09 AU AU2012229316A patent/AU2012229316B2/en not_active Ceased
- 2012-03-09 AU AU2012229300A patent/AU2012229300B2/en not_active Ceased
- 2012-03-09 SG SG2013066840A patent/SG193320A1/en unknown
- 2012-03-09 ES ES12710836.3T patent/ES2562332T3/es active Active
- 2012-03-09 PT PT127108363T patent/PT2683384E/pt unknown
- 2012-03-09 JP JP2013557904A patent/JP2014510078A/ja not_active Withdrawn
- 2012-03-09 MX MX2013010217A patent/MX2013010217A/es active IP Right Grant
- 2012-03-09 WO PCT/US2012/028498 patent/WO2012125459A1/en not_active Ceased
- 2012-03-09 TW TW101108231A patent/TWI542349B/zh not_active IP Right Cessation
- 2012-03-09 PH PH1/2013/501837A patent/PH12013501837A1/en unknown
- 2012-03-09 EP EP15197498.7A patent/EP3025715A1/en not_active Withdrawn
- 2012-03-09 HU HUE12710836A patent/HUE027481T2/en unknown
- 2012-03-09 MX MX2013010153A patent/MX2013010153A/es active IP Right Grant
- 2012-03-09 CN CN201280022744.2A patent/CN103561743A/zh active Pending
- 2012-03-09 RU RU2013145524/15A patent/RU2013145524A/ru not_active Application Discontinuation
- 2012-03-09 CN CN201280022778.1A patent/CN103561744A/zh active Pending
- 2012-03-09 CA CA 2829592 patent/CA2829592A1/en not_active Abandoned
- 2012-03-09 HR HRP20160056TT patent/HRP20160056T1/hr unknown
- 2012-03-09 SI SI201230451A patent/SI2683384T1/sl unknown
- 2012-03-09 RS RS20160067A patent/RS54553B1/sr unknown
- 2012-03-09 AR ARP120100782 patent/AR085651A1/es unknown
- 2012-03-09 WO PCT/US2012/028538 patent/WO2012125475A1/en not_active Ceased
- 2012-03-09 EP EP12710411.5A patent/EP2683383B1/en not_active Not-in-force
- 2012-03-09 EA EA201691939A patent/EA201691939A1/ru unknown
- 2012-03-09 RU RU2013145556/15A patent/RU2013145556A/ru not_active Application Discontinuation
- 2012-03-09 DK DK12710836.3T patent/DK2683384T3/da active
- 2012-03-09 EA EA201391319A patent/EA201391319A1/ru unknown
- 2012-03-09 KR KR20137026402A patent/KR20140019364A/ko not_active Withdrawn
-
2013
- 2013-08-15 ZA ZA2013/06148A patent/ZA201306148B/en unknown
- 2013-08-15 IL IL227990A patent/IL227990B/en active IP Right Grant
- 2013-08-21 ZA ZA2013/06305A patent/ZA201306305B/en unknown
- 2013-09-01 IL IL228230A patent/IL228230A/en not_active IP Right Cessation
- 2013-09-09 NI NI201300082A patent/NI201300082A/es unknown
- 2013-09-09 NI NI201300081A patent/NI201300081A/es unknown
-
2014
- 2014-11-05 US US14/533,941 patent/US20150126538A1/en not_active Abandoned
-
2016
- 2016-01-12 US US14/993,998 patent/US20160136167A1/en not_active Abandoned
- 2016-02-02 CY CY20161100088T patent/CY1117430T1/el unknown
- 2016-02-09 SM SM201600034T patent/SMT201600034B/xx unknown
- 2016-12-22 JP JP2016248598A patent/JP2017081959A/ja active Pending
-
2017
- 2017-01-24 JP JP2017009923A patent/JP6348192B2/ja not_active Expired - Fee Related
- 2017-02-22 US US15/439,879 patent/US20170165266A1/en not_active Abandoned
- 2017-04-11 US US15/484,850 patent/US20180055844A1/en not_active Abandoned
- 2017-06-28 AU AU2017204402A patent/AU2017204402A1/en not_active Abandoned
- 2017-08-04 AU AU2017210633A patent/AU2017210633A1/en not_active Abandoned
-
2018
- 2018-05-30 JP JP2018103019A patent/JP2018168159A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014508780A5 (enExample) | ||
| RU2013145556A (ru) | Применение 3-(5-амино-2-метил-4-оксохиназолин-3(4н)-ил)пиперидин-2,6-диона в лечении иммунных и воспалительных заболеваний | |
| ES2668300T3 (es) | Inhibidores de SSAO de 3-haloamidina sustituida y usos de los mismos | |
| ES2780825T3 (es) | Compuestos aromáticos sustituidos para el tratamiento de la fibrosis pulmonar, la fibrosis del hígado, la fibrosis de la piel y la fibrosis cardíaca | |
| EP1485089B1 (en) | Combination treatments for chemokine-mediated diseases | |
| AU2013299625B2 (en) | Treatment of immune-related and inflammatory diseases | |
| ES2741439T3 (es) | Compuestos aromáticos sustituidos | |
| WO2003059886A1 (en) | Acyl sulfonamide derivative | |
| JP2003519102A5 (enExample) | ||
| US20190270733A1 (en) | Quinoline and Isoquinoline Based HDAC Inhibitors and Methods of Use Thereof | |
| JPH0250902B2 (enExample) | ||
| JP2005272453A (ja) | アミノアルコール化合物 | |
| WO2012000377A1 (zh) | 包含左卡尼汀和羟苯磺酸盐的药物组合物 | |
| WO2017030892A1 (en) | Histone deacetylase inhibitors and methods for use thereof | |
| WO2018236913A1 (en) | Calpain modulators and therapeutic uses thereof | |
| KR102679975B1 (ko) | 지방독성 손상을 저감하기 위한 화합물 | |
| MXPA04004572A (es) | Metodo para el tratamiento de enfermedades autoinmunes. | |
| WO2020177291A1 (zh) | 法舒地尔复合盐及其制备方法和用途 | |
| JP2005514352A6 (ja) | 自己免疫疾患の治療法 | |
| JP7498504B2 (ja) | 脳神経または心臓保護剤としてのアミノチオール系化合物の使用 | |
| CN115515603A (zh) | 用于治疗戊型肝炎的双环和单环核苷类似物 | |
| CN104470510A (zh) | 一种基于前列腺素的支气管松解药 | |
| WO2024193451A1 (en) | Triazine derivatives, method of making and method of using thereof | |
| US6140335A (en) | Use of mizolastine for treating inflammatory diseases associated with 5-lipoxygenase | |
| OA21046A (en) | BI- and monocyclic nucleoside analogs for treatment of hepatitis E. |